Topsalysin: Completed Phase III enrollment

Sophiris completed enrollment in the double-blind, vehicle-controlled, international Phase III PLUS-1 trial evaluating a single intraprostatic injection of 0.6 ug/g prostate PRX302. The company said the trial enrolled at least 440 patients as designed, but declined to disclose the exact number of patients enrolled. ...